![ECOG-ACRIN logo[19516]275×75](https://blog.ecog-acrin.org/wp-content/uploads/2021/03/ECOG-ACRIN-logo19516275x75.png)
July 31, 2026
An update on our NCTN grant award, practice-changing multiple myeloma research, a promising new lung cancer study, and highlights from the Comis Translational Science Symposium
July 31, 2026
This trial is evaluating a new immunotherapy approach for patients with high-risk multiple myeloma that has returned after initial treatment
July 31, 2026
The latest findings in breast cancer, cardiotoxicity, leukemia, lung cancer, myeloma, NCI-MATCH, and smoking cessation support during cancer treatment
July 31, 2026
Timely information about research presented at medical meetings, recognition of research leaders, and more
July 31, 2026
This trial is testing an immune-based treatment combination (teclistamab and pomalidomide) for patients with multiple myeloma that has come back early
April 24, 2026
This phase 3 trial seeks to determine if there is any survival benefit from adding a fourth drug to induction therapy—and if so, in which patients
December 19, 2025
The trials explore potential treatment improvements for different cancer types: bladder, lung, lymphoma, myeloma, and stomach
August 28, 2025
This clinical trial aims to improve outcomes by utilizing novel myeloma targeting therapy to reverse kidney failure
February 10, 2023
These three trials are open and enrolling adults with multiple myeloma or at high risk of developing the disease
December 22, 2021
Researchers with the Leukemia, Lymphoma, and Myeloma Committees presented a range of findings pertaining to treatments, patient-reported outcomes, and genomics
August 17, 2021
This randomized phase III trial aims to determine if the addition of ixazomib to lenalidomide improves overall survival in patients with multiple myeloma
May 28, 2021
Researchers with the ECOG-ACRIN Cancer Research Group and PrECOG, LLC will present a wide range of research findings at the 2021 ASCO Annual Meeting